http://www.law360.com/ Latest articles for organization: Eli Lilly and Company Copyright 2009 Portfolio Media, Inc. en-US http://www.law360.com/images/headings/logo.gif http://www.law360.com/ http://www.law360.com/articles/135122 Karen B. Dow, a biotechnology and pharmaceutical patent attorney who formerly was patent counsel for Eli Lilly & Co., has joined intellectual property firm Sughrue Mion PLLC. http://www.law360.com/articles/135122 http://www.law360.com/articles/134620 A federal judge has dismissed a wrongful death suit against Eli Lilly & Co., rejecting the plaintiff's bid to add a new expert after the judge excluded testimony from a psychiatrist for using flawed methods to show that Prozac caused a man to kill himself, his wife and his dog. http://www.law360.com/articles/134620 http://www.law360.com/articles/132958 Employers in the life sciences industry may be directly in the path of the growing tsunami of wage-and-hour class actions causing great upheaval and expense in retail, financial services and other industries. It is important to understand the key risk factors for employers in an industry where research personnel, pharmaceutical sales representatives and independent contractors are prevalent, says Joseph P. Breen of Seyfarth Shaw LLP. http://www.law360.com/articles/132958 http://www.law360.com/articles/133493 Eli Lilly & Co. will pay Utah $24 million in the latest state settlement over the pharmaceutical giant's alleged off-label marketing of the antipsychotic Zyprexa, state officials said Wednesday. http://www.law360.com/articles/133493 http://www.law360.com/articles/132025 The U.S. Food and Drug Administration has issued a warning about possible kidney problems associated with the use of Byetta, a diabetes drug marketed by Amylin Pharmaceuticals Inc. and Eli Lilly & Co. http://www.law360.com/articles/132025 http://www.law360.com/articles/131628 Eli Lilly & Co. is appealing a federal court ruling that invalidated one of the patents in an infringement dispute with generic-drug maker Sun Pharmaceutical Industries Ltd. over the cancer treatment Gemzar. http://www.law360.com/articles/131628 http://www.law360.com/articles/131475 British drugmaker Shire PLC has received a subpoena from U.S. investigators seeking documents related to the sales and marketing of three drugs, including Adderall, the company said. http://www.law360.com/articles/131475 http://www.law360.com/articles/131183 AstraZeneca Pharmaceuticals LP has agreed to pay $520 million to settle an investigation by the U.S. Attorney's Office for the Eastern District of Pennsylvania into sales and marketing practices for the company's antipsychotic drug Seroquel. http://www.law360.com/articles/131183 http://www.law360.com/articles/130180 In the latest of a series of state settlements over Zyprexa, Eli Lilly & Co. has agreed to pay $45 million to South Carolina to resolve allegations it improperly marketed the antipsychotic drug for off-label uses. http://www.law360.com/articles/130180 http://www.law360.com/articles/129917 India and Brazil are reportedly on the verge of launching a formal complaint with the World Trade Organization as part of a long-simmering battle with the European Union over the frequent seizure of generic drugs at European ports over alleged patent violations. http://www.law360.com/articles/129917 http://www.law360.com/articles/129028 The New York Intellectual Property Law Association has filed an amicus brief in the appeal of the Ariad Pharmaceuticals Inc. patent suit — which could make patents easier to prosecute and tougher to invalidate — saying the court should look to the enablement requirement to settle the case. http://www.law360.com/articles/129028 http://www.law360.com/articles/120614 Patent-eligibility should be a low-threshold determination based on the broad statutory language, limited only by due consideration of the constitutional objective of promoting the progress of science and useful arts, says intellectual property attorney Bradford Paul Schmidt. http://www.law360.com/articles/120614 http://www.law360.com/articles/128078 Eli Lilly & Co. has agreed to pay $13 million to settle a lawsuit brought by the state of Idaho over the drugmaker's promotion and marketing of the antipsychotic Zyprexa. http://www.law360.com/articles/128078 http://www.law360.com/articles/127717 Teva Pharmaceutical Industries Ltd. has struck back with patent invalidity counterclaims against rival Gilead Sciences Inc. in an infringement case involving drug treatments for HIV. http://www.law360.com/articles/127717 http://www.law360.com/articles/123920 In a case that could make patents easier to prosecute and tougher to invalidate, a federal appeals court is gearing up for an en banc rehearing of Ariad Pharmaceuticals Inc.’s patent infringement fight against Eli Lilly & Co. over osteoporosis drug Evista and septic shock treatment Xigris. http://www.law360.com/articles/123920 http://www.law360.com/articles/127048 Eli Lilly & Co. indicated Wednesday that it would settle a lawsuit with South Carolina just as the state was set to seek $6 billion in a trial over allegations that the drug company improperly marketed its antipsychotic Zyprexa for off-label uses. http://www.law360.com/articles/127048 http://www.law360.com/articles/120819 Memorandum decisions are now the norm and many are perfunctory. Last year, amazingly, the Eighth Circuit summarily affirmed without any substantive opinion over 30 percent of the time. That’s disturbing, and the problem may get worse now that unpublished opinions can be cited, says Dan L. Bagatell, appellate co-chair at Perkins Coie LLP. http://www.law360.com/articles/120819 http://www.law360.com/articles/125218 Eli Lilly & Co. is set to fork over $25.1 million to settle a lawsuit brought by the Connecticut Attorney General's Office for allegedly marketing its antipsychotic Zyprexa for unapproved uses and concealing the drug's serious side effects for more than a decade. http://www.law360.com/articles/125218 http://www.law360.com/articles/124308 A federal judge has permanently blocked Teva Pharmaceuticals USA Inc. from launching a copy of Eli Lilly & Co.'s blockbuster osteoporosis drug Evista, rejecting Teva's argument that four Lilly patents are invalid. http://www.law360.com/articles/124308 http://www.law360.com/articles/121038 In its suit against Eli Lilly & Co., the state of South Carolina reportedly has disclosed notes from company sales representatives that indicate the pharmaceutical giant used golf bets to spur prescriptions of antipsychotic treatment Zyprexa and paid doctors to take part in a speakers program in return for prescribing the drug. http://www.law360.com/articles/121038